Vistoli, G; De Maddis, D; Cipak, A; Zarkovic, N; Carini, M; Aldini, G (Aug 2013). “Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation.”. Free Radic Res.47 (12): Suppl 1:3–27. doi:10.3109/10715762.2013.815348. PMID10946212.
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006). “Advanced glycation end products: sparking the development of diabetic vascular injury”. Circulation114 (6): 597–605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID16894049.
Song X, Bao M, Li D, Li YM (1999). “Advanced glycation in D-galactose induced mouse aging model”. Mech Ageing Dev108 (3): 239–51. doi:10.1016/S0047-6374(99)00022-6. PMID10405984.
Brownlee, M (June 2005). “The pathobiology of diabetic complications: a unifying mechanism.”. Diabetes54 (6): 1615–25. doi:10.2337/diabetes.54.6.1615. PMID15919781.
Dominiczak MH (2003). “Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine”. Clin. Chem. Lab. Med.41 (9): 1266–78. doi:10.1515/CCLM.2003.194. PMID14598880.
Glenn, J.; Stitt, A. (2009). “The role of advanced glycation end products in retinal ageing and disease”. Biochimica et Biophysica Acta1790 (10): 1109–1116. doi:10.1016/j.bbagen.2009.04.016. PMID19409449.
Yan, S. F.; D'Agati, V.; Schmidt, A. M.; Ramasamy, R. (2007). “Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging”. Current molecular medicine7 (8): 699–710. doi:10.2174/156652407783220732. PMID18331228.
Pertyńska-Marczewska, M; Głowacka, E; Sobczak, M; Cypryk, K; Wilczyński, J (February 2009). “Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies.”. American journal of reproductive immunology (New York, N.Y. : 1989)61 (2): 175–82. doi:10.1111/j.1600-0897.2008.00679.x. PMID19143681.
Srikanth, V; Maczurek, A; Phan, T; Steele, M; Westcott, B; Juskiw, D; Münch, G (May 2011). “Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.”. Neurobiology of Aging32 (5): 763–77. doi:10.1016/j.neurobiolaging.2009.04.016. PMID19464758.
Simm, A; Wagner, J; Gursinsky, T; Nass, N; Friedrich, I; Schinzel, R; Czeslik, E; Silber, RE et al. (July 2007). “Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?”. Experimental Gerontology42 (7): 668–75. doi:10.1016/j.exger.2007.03.006. PMID17482402.
Shaikh S, Nicholson LF (2008-07). “Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.”. J Neurosci Res.86 (9): 2071-82. doi:10.1002/jnr.21644. PMID18335520.
Fuentealba D, Friguet B, Silva E (2009). “Advanced glycation endproducts induce photocrosslinking and oxidation of bovine lens proteins through type-I mechanism.”. Photochem Photobiol.85 (1): 185-94. doi:10.1111/j.1751-1097.2008.00415.x. PMID18673320.
Gul A, Rahman MA, Hasnain SN (2009-06). “Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients.”. Graefes Arch Clin Exp Ophthalmol.247 (6): 809-14. doi:10.1007/s00417-008-1027-9. PMID19198870.
Haus, JM; Carrithers, JA; Trappe, SW; Trappe, TA (December 2007). “Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle.”. Journal of applied physiology (Bethesda, Md. : 1985)103 (6): 2068–76. doi:10.1152/japplphysiol.00670.2007. PMID17901242.
Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995). “Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose”. Biochemistry34 (11): 3702–9. doi:10.1021/bi00011a027. PMID7893666.
Gugliucci A, Mehlhaff K, Kinugasa E (2007). “Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance”. Clin. Chim. Acta377 (1–2): 213–20. doi:10.1016/j.cca.2006.09.028. PMID17118352.
Svistounov D, Smedsrød B (2004). “Hepatic clearance of advanced glycation end products (AGEs)—myth or truth?”. J. Hepatol.41 (6): 1038–40. doi:10.1016/j.jhep.2004.10.004. PMID15582139.
Hira Zafar, (26 June 2012). “Inhibition of protein glycation and advanced glycation end products by ascorbic acid”. African Journal of Biotechnology11 (51). doi:10.5897/AJB11.4172.
Guiotto A, Calderan A, Ruzza P, Borin G (2005). “Carnosine and carnosine-related antioxidants: a review”. Current Medicinal Chemistry12 (20): 2293–2315. doi:10.2174/0929867054864796. PMID16181134.
Ryoji Nagai, Jun-ichi Shirakawa, Rei-ichi Ohno, Narumi Moroishi, M. Nagai (2013). “Inhibition of AGEs formation by natural products”. Amino acids46 (2). doi:10.1007/s00726-013-1487-z.
“N-Acetyl Cysteine Attenuated the Deleterious Effects of Advanced Glycation End-Products on the Kidney of Non-Diabetic Rats”. Cellular Physiology and Biochemistry40 (3-4). (2016). doi:10.1159/000452574.
Upadhyay A, Tuenter E, Ahmad R, et al. (2014-08). “Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors.”. Planta Med.80 (12): 1001-8. doi:10.1055/s-0034-1382949. PMID25098935.
Vasan, S; Zhang, X; Zhang, X; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P (Jul 18, 1996). “An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.”. Nature382 (6588): 275–8. doi:10.1038/382275a0. PMID8717046.
Monnier, V. M., Mustata, G. T., Biemel, K. L., Reihl, O., Lederer, M. O., Zhenyu, D. (2005). “Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: An update on "a puzzle nearing resolution"”. Annals of the New York Academy of Sciences1043: 533–544. doi:10.1196/annals.1333.061. PMID16037276.
Furber, J.D. (2006). “Extracellular glycation crosslinks: Prospects for removal”. Rejuvenation Research (Elsevier Inc.) 9 (2): 274–278. doi:10.1089/rej.2006.9.274. PMID16706655.
Vistoli, G; De Maddis, D; Cipak, A; Zarkovic, N; Carini, M; Aldini, G (Aug 2013). “Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation.”. Free Radic Res.47 (12): Suppl 1:3–27. doi:10.3109/10715762.2013.815348. PMID10946212.
Ienaga K, Nakamura K, Hochi T, et al (1995). “Crosslines, fluorophores in the AGE-related cross-linked proteins.”. Contrib Nephrol.112: 42-51. PMID7554992.
Goldin A, Beckman JA, Schmidt AM, Creager MA (2006). “Advanced glycation end products: sparking the development of diabetic vascular injury”. Circulation114 (6): 597–605. doi:10.1161/CIRCULATIONAHA.106.621854. PMID16894049.
Song X, Bao M, Li D, Li YM (1999). “Advanced glycation in D-galactose induced mouse aging model”. Mech Ageing Dev108 (3): 239–51. doi:10.1016/S0047-6374(99)00022-6. PMID10405984.
Brownlee, M (June 2005). “The pathobiology of diabetic complications: a unifying mechanism.”. Diabetes54 (6): 1615–25. doi:10.2337/diabetes.54.6.1615. PMID15919781.
Dominiczak MH (2003). “Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine”. Clin. Chem. Lab. Med.41 (9): 1266–78. doi:10.1515/CCLM.2003.194. PMID14598880.
Gugliucci, A (October 2000). “Glycation as the glucose link to diabetic complications.”. The Journal of the American Osteopathic Association100 (10): 621–34. PMID11105451.
Glenn, J.; Stitt, A. (2009). “The role of advanced glycation end products in retinal ageing and disease”. Biochimica et Biophysica Acta1790 (10): 1109–1116. doi:10.1016/j.bbagen.2009.04.016. PMID19409449.
Yan, S. F.; D'Agati, V.; Schmidt, A. M.; Ramasamy, R. (2007). “Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging”. Current molecular medicine7 (8): 699–710. doi:10.2174/156652407783220732. PMID18331228.
Pertyńska-Marczewska, M; Głowacka, E; Sobczak, M; Cypryk, K; Wilczyński, J (February 2009). “Glycation endproducts, soluble receptor for advanced glycation endproducts and cytokines in diabetic and non-diabetic pregnancies.”. American journal of reproductive immunology (New York, N.Y. : 1989)61 (2): 175–82. doi:10.1111/j.1600-0897.2008.00679.x. PMID19143681.
Tan, KC; Chow, WS; Lam, JC; Lam, B; Bucala, R; Betteridge, J; Ip, MS (March 2006). “Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea.”. Sleep29 (3): 329–33. PMID16553018.
Srikanth, V; Maczurek, A; Phan, T; Steele, M; Westcott, B; Juskiw, D; Münch, G (May 2011). “Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.”. Neurobiology of Aging32 (5): 763–77. doi:10.1016/j.neurobiolaging.2009.04.016. PMID19464758.
Simm, A; Wagner, J; Gursinsky, T; Nass, N; Friedrich, I; Schinzel, R; Czeslik, E; Silber, RE et al. (July 2007). “Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery?”. Experimental Gerontology42 (7): 668–75. doi:10.1016/j.exger.2007.03.006. PMID17482402.
Zimmerman GA, Meistrell M 3rd, Bloom O, et al. (1995-04-25). “Neurotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine.”. Proc Natl Acad Sci USA.92 (9): 3744-8. PMID7731977.
Shaikh S, Nicholson LF (2008-07). “Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.”. J Neurosci Res.86 (9): 2071-82. doi:10.1002/jnr.21644. PMID18335520.
Fuentealba D, Friguet B, Silva E (2009). “Advanced glycation endproducts induce photocrosslinking and oxidation of bovine lens proteins through type-I mechanism.”. Photochem Photobiol.85 (1): 185-94. doi:10.1111/j.1751-1097.2008.00415.x. PMID18673320.
Gul A, Rahman MA, Hasnain SN (2009-06). “Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients.”. Graefes Arch Clin Exp Ophthalmol.247 (6): 809-14. doi:10.1007/s00417-008-1027-9. PMID19198870.
Haus, JM; Carrithers, JA; Trappe, SW; Trappe, TA (December 2007). “Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle.”. Journal of applied physiology (Bethesda, Md. : 1985)103 (6): 2068–76. doi:10.1152/japplphysiol.00670.2007. PMID17901242.
Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995). “Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose”. Biochemistry34 (11): 3702–9. doi:10.1021/bi00011a027. PMID7893666.
Gugliucci A, Mehlhaff K, Kinugasa E (2007). “Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance”. Clin. Chim. Acta377 (1–2): 213–20. doi:10.1016/j.cca.2006.09.028. PMID17118352.
Svistounov D, Smedsrød B (2004). “Hepatic clearance of advanced glycation end products (AGEs)—myth or truth?”. J. Hepatol.41 (6): 1038–40. doi:10.1016/j.jhep.2004.10.004. PMID15582139.
Guiotto A, Calderan A, Ruzza P, Borin G (2005). “Carnosine and carnosine-related antioxidants: a review”. Current Medicinal Chemistry12 (20): 2293–2315. doi:10.2174/0929867054864796. PMID16181134.
Upadhyay A, Tuenter E, Ahmad R, et al. (2014-08). “Kavalactones, a novel class of protein glycation and lipid peroxidation inhibitors.”. Planta Med.80 (12): 1001-8. doi:10.1055/s-0034-1382949. PMID25098935.
Vasan, S; Zhang, X; Zhang, X; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P (Jul 18, 1996). “An agent cleaving glucose-derived protein crosslinks in vitro and in vivo.”. Nature382 (6588): 275–8. doi:10.1038/382275a0. PMID8717046.
Monnier, V. M., Mustata, G. T., Biemel, K. L., Reihl, O., Lederer, M. O., Zhenyu, D. (2005). “Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: An update on "a puzzle nearing resolution"”. Annals of the New York Academy of Sciences1043: 533–544. doi:10.1196/annals.1333.061. PMID16037276.
Furber, J.D. (2006). “Extracellular glycation crosslinks: Prospects for removal”. Rejuvenation Research (Elsevier Inc.) 9 (2): 274–278. doi:10.1089/rej.2006.9.274. PMID16706655.